Azithromycin

Evidence Level: L5

Predicted Indications: 10

Azithromycin

Pharmacist Assessment Report

Azithromycin: From Bacterial Infections to Polyclonal Hyperviscosity Syndrome

One-Sentence Summary

Azithromycin is a macrolide antibiotic originally used for bacterial infections such as streptococcal and staphylococcal infections, bacterial pneumonia, and conjunctivitis. The TxGNN model predicts it may be effective for polyclonal hyperviscosity syndrome, but no clinical trials and no publications currently support this prediction, so it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Streptococcal infection, bacterial pneumonia, staphylococcal infection, conjunctivitis, and others (the approved indication text on the India licences is blank)
Predicted New Indication	Polyclonal hyperviscosity syndrome
TxGNN Prediction Score	0.9981
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, azithromycin is a macrolide antibiotic, its efficacy in bacterial infections is established, and its antibacterial action does not plausibly address the predicted condition.

Polyclonal hyperviscosity syndrome is caused by excess circulating immunoglobulins. Nothing in the data compiled for this report links azithromycin to this mechanism. The high score (0.9981) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The evidence supporting it is at the model-prediction level, so it should be treated as a hypothesis rather than a finding.

The other top-ranked predictions are also weakly supported:

Rank	Predicted Indication	Score	Evidence Level	Comment
2	Hyperamylasemia	0.9981	L5	A laboratory finding with heterogeneous causes; no supporting data
3	Congenital analbuminemia	0.9979	L5	Rare genetic disorder; the score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence
4	Punctate epithelial keratoconjunctivitis	0.9978	L5	Weak indirect rationale; the only paper is an unrelated microsporidial case report
7	Monoclonal gammopathy	0.9961	L5	In vitro myeloma data suggest macrolides block autophagy; no efficacy data
9	Septicemic plague	0.9952	L5	In vitro study showed poor azithromycin activity against Yersinia pestis
10	Congenital hematological disorder (sickle cell disease)	0.9940	L5	Both sickle-cell trials were withdrawn with no enrollment

Of these, the sickle cell disease direction (anti-inflammatory effects to reduce acute chest syndrome) and the myeloma/plasma cell direction have the most plausible hypotheses, but neither has clinical data yet.

Clinical Trial Evidence

Currently no related clinical trials are registered for polyclonal hyperviscosity syndrome.

For reference, the lower-ranked prediction of congenital hematological disorder (sickle cell disease) has these trials:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02960503	Phase 1/2	Withdrawn	0	Macrolide therapy to improve FEV1 in adults with sickle cell disease; no data generated
NCT02630394	Phase 1	Withdrawn	0	Azithromycin prophylaxis for acute chest syndrome in sickle cell disease; no data generated
NCT04278404	N/A	Recruiting	5000	General pharmacokinetics and safety of understudied drugs in children; not specific to this indication

Literature Evidence

Currently no related literature is available for polyclonal hyperviscosity syndrome.

For reference, the strongest items under the other predictions are:

PMID	Year	Type	Journal	Key Findings
23546223	2013	Preclinical (in vitro)	Int J Oncol	Macrolides including azithromycin blocked autophagy flux and enhanced bortezomib cytotoxicity in myeloma cells
8540736	1995	In vitro susceptibility	Antimicrob Agents Chemother	Azithromycin showed poor activity against 78 Yersinia pestis strains
12698575	2002	Preclinical (animal)	Antibiot Khimioter	Azithromycin was highly active in experimental brucellosis
26408070	2015	Systematic review (Cochrane)	Cochrane Database Syst Rev	Antibiotics for preventing lower respiratory tract infections in high-risk children; indirect relevance

India Market Information

Azithromycin is marketed in India with 20 valid single-ingredient registrations. The approved indication text is not recorded on these licences. Five representative registrations:

Authorization Number	Product Name	Dosage Form	Approved Indication
16792	Azimycin 500mg Tablet	Strip of 3 tablets	Not specified
18709	Azelac 250mg Tablet	Strip of 6 tablets	Not specified
129612	Loromycin 500mg Capsule	Strip of 3 capsules	Not specified
148642	Mythro 200mg Syrup	Bottle of 15 ml syrup	Not specified
19154	Azintra 100mg Tablet DT	Strip of 10 dispersible tablets	Not specified

Safety Considerations

Contraindications and disease associations (from the knowledge graph, not label text): long QT syndrome, familial long QT syndrome, torsades de pointes, liver disease, gallbladder disease, Clostridium difficile colitis, perinatal necrotizing enterocolitis, myasthenia gravis, neuromuscular junction disease, hearing disorder, and auditory system disease.
Drug Interactions: 235 interactions were identified. The major-severity ones among those listed are:
- Cisapride (Major)
- Dolasetron (Major)
Moderate interactions include famotidine, loperamide, clarithromycin, levofloxacin, granisetron, and aluminum and magnesium antacids, as well as several laxatives. Many of the QT-related interactions are consistent with the long QT contraindications above.

Package insert warnings were not available for this report, so please refer to the package insert for the full safety profile.

Conclusion and Next Steps

Decision: Hold

Rationale: The 0.9981 TxGNN score for polyclonal hyperviscosity syndrome comes from the TxGNN model (deep learning) only and may reflect similarities the model learned between related diseases, not biological evidence. There are no trials or publications, and azithromycin’s antibacterial action does not plausibly address hyperviscosity caused by excess immunoglobulins. No prediction on the list currently reaches the level of evidence needed to advance. Sickle cell disease and plasma cell disorders are the only directions worth tracking as research questions.

To proceed, the following is needed:

Mechanism of action data for azithromycin to allow a mechanistic-link analysis
Package insert warnings and contraindications from the India regulator, which are currently missing and block safety screening
Any experimental or clinical evidence for the predicted indication; otherwise, redirect effort to the sickle cell disease (anti-inflammatory) or plasma cell disorder hypotheses
A QT-prolongation and drug-interaction risk assessment if any new indication moves forward
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.